Combo inhalers get PBAC approval for mild asthma

PBS funding now likely for Symbicort as a first-line therapy

The PBAC has declared budesonide-formoterol combination inhalers should be funded as a first-line treatment for mild asthma for adults and adolescents.


It is a reversal from the expert committee’s announcement in August last year that budesonide-formoterol inhalers had “uncertain” clinical benefits for patients with mild asthma and should not be subsidised by the taxpayer.

AstraZeneca, which filed the application for its combination inhaler Symbicort, was not deterred by